Gufic Biosciences Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Gufic Biosciences.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	17.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

There's Reason For Concern Over Gufic Biosciences Limited's (NSE:GUFICBIO) Massive 26% Price Jump

Nov 07

We Think You Should Be Aware Of Some Concerning Factors In Gufic Biosciences' (NSE:GUFICBIO) Earnings

Jun 06

Is Gufic Biosciences (NSE:GUFICBIO) Using Too Much Debt?

Jun 17

These 4 Measures Indicate That Gufic Biosciences (NSE:GUFICBIO) Is Using Debt Reasonably Well

Sep 02

Should You Be Adding Gufic Biosciences (NSE:GUFICBIO) To Your Watchlist Today?

May 07

Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock

Dec 07

This Is The Reason Why We Think Gufic Biosciences Limited's (NSE:GUFICBIO) CEO Might Be Underpaid

Sep 15

Is Now The Time To Put Gufic Biosciences (NSE:GUFICBIO) On Your Watchlist?

Aug 12

Gufic Biosciences' (NSE:GUFICBIO) Performance Is Even Better Than Its Earnings Suggest

Jun 11

If You Like EPS Growth Then Check Out Gufic Biosciences (NSE:GUFICBIO) Before It's Too Late

Mar 19

What Percentage Of Gufic Biosciences Limited (NSE:GUFICBIO) Shares Do Insiders Own?

Mar 01

Here's What Gufic Biosciences Limited's (NSE:GUFICBIO) Shareholder Ownership Structure Looks Like

Dec 01

Gufic Biosciences (NSE:GUFICBIO) Has A Somewhat Strained Balance Sheet

Nov 13

The Gufic Biosciences (NSE:GUFICBIO) Share Price Has Gained 116%, So Why Not Pay It Some Attention?

Oct 19

Can Gufic Biosciences Limited's (NSE:GUFICBIO) ROE Continue To Surpass The Industry Average?

Sep 14

I Built A List Of Growing Companies And Gufic Biosciences (NSE:GUFICBIO) Made The Cut

Aug 24

Investors Appear Satisfied With Gufic Biosciences Limited's (NSE:GUFICBIO) Prospects

Aug 03

Earnings Tell The Story For Gufic Biosciences Limited (NSE:GUFICBIO)

Jul 09

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Gufic Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:GUFICBIO - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	8,038	849	-246	697	N/A
6/30/2024	8,145	864	N/A	N/A	N/A
3/31/2024	8,067	861	-1,202	-75	N/A
12/31/2023	7,847	842	N/A	N/A	N/A
9/30/2023	7,604	823	-1,639	159	N/A
6/30/2023	7,204	793	N/A	N/A	N/A
3/31/2023	6,906	797	-2,142	-266	N/A
12/31/2022	6,798	819	N/A	N/A	N/A
9/30/2022	6,744	826	-1,652	-355	N/A
6/30/2022	6,937	857	N/A	N/A	N/A
3/31/2022	7,792	958	188	1,062	N/A
12/31/2021	7,489	884	N/A	N/A	N/A
9/30/2021	7,434	829	1,662	1,798	N/A
6/30/2021	6,777	769	N/A	N/A	N/A
3/31/2021	4,877	442	749	873	N/A
12/31/2020	4,005	305	N/A	N/A	N/A
9/30/2020	3,538	243	-14	511	N/A
6/30/2020	3,195	123	N/A	N/A	N/A
3/31/2020	3,788	227	73	471	N/A
12/31/2019	3,681	243	N/A	N/A	N/A
9/30/2019	3,580	232	4	254	N/A
6/30/2019	3,640	249	N/A	N/A	N/A
3/31/2019	3,508	219	-79	52	N/A
12/31/2018	3,334	164	N/A	N/A	N/A
9/30/2018	3,353	168	N/A	N/A	N/A
6/30/2018	3,192	164	N/A	N/A	N/A
3/31/2018	3,056	165	N/A	-48	N/A
12/31/2017	2,887	181	N/A	N/A	N/A
9/30/2017	2,651	154	N/A	N/A	N/A
6/30/2017	2,544	124	N/A	N/A	N/A
3/31/2017	2,455	90	N/A	-41	N/A
12/31/2016	2,419	105	N/A	N/A	N/A
9/30/2016	2,329	98	N/A	N/A	N/A
6/30/2016	2,201	88	N/A	N/A	N/A
3/31/2016	2,022	73	N/A	-43	N/A
12/31/2015	1,806	62	N/A	N/A	N/A
9/30/2015	1,588	45	N/A	N/A	N/A
6/30/2015	1,500	36	N/A	N/A	N/A
3/31/2015	1,516	42	N/A	112	N/A
12/31/2014	1,533	43	N/A	N/A	N/A
9/30/2014	1,503	47	N/A	N/A	N/A
6/30/2014	1,366	47	N/A	N/A	N/A
3/31/2014	1,230	43	N/A	109	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if GUFICBIO's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if GUFICBIO's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if GUFICBIO's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if GUFICBIO's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if GUFICBIO's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if GUFICBIO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/31 23:18
End of Day Share Price	2024/12/31 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gufic Biosciences Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Anil Burra	FirstCall Research
Naveed MD.	FirstCall Research

Gufic Biosciences Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Less than half of directors are independent

Gufic Biosciences Limited Announces Cessation of Gopal Madhavbhai Daptari as Independent Director

Second quarter 2025 earnings released: EPS: ₹2.17 (vs ₹2.39 in 2Q 2024)

Gufic Biosciences Limited to Report Q2, 2025 Results on Nov 14, 2024

There's Reason For Concern Over Gufic Biosciences Limited's (NSE:GUFICBIO) Massive 26% Price Jump

Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2024

Gufic Biosciences Limited Announces Cessation of Shreyas Patel as Independent Director and New Composition of Committees

Dividend of ₹0.10 announced

Gufic Biosciences Limited, Annual General Meeting, Sep 25, 2024

First quarter 2025 earnings released: EPS: ₹2.08 (vs ₹2.13 in 1Q 2024)

Gufic Biosciences Limited Announces Resignation of Bal Ram Singh as Non-Executive and Non-Independent Director

Gufic Biosciences Limited to Report Q1, 2025 Results on Aug 14, 2024

Gufic Biosciences Limited Announces Cessation of Rabi Sahoo as Independent Director and Chairman of Stakeholders Relationship Committee and Member of Audit Committee

Investor sentiment improves as stock rises 19%

We Think You Should Be Aware Of Some Concerning Factors In Gufic Biosciences' (NSE:GUFICBIO) Earnings

Gufic Biosciences Limited Proposes Recommendation of Final Dividend for the Financial Year 2023-24

Full year 2024 earnings released: EPS: ₹8.74 (vs ₹8.22 in FY 2023)

Third quarter 2024 earnings released: EPS: ₹2.23 (vs ₹2.10 in 3Q 2023)

Second quarter 2024 earnings released: EPS: ₹2.39 (vs ₹2.09 in 2Q 2023)

Gufic Biosciences Limited announced that it has received INR 999.9 million in funding from Motilal Oswal Financial Services Limited

Upcoming dividend of ₹0.10 per share

Gufic Biosciences Limited to Report Q2, 2024 Results on Nov 14, 2023

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

New minor risk - Shareholder dilution

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

First quarter 2024 earnings released: EPS: ₹2.13 (vs ₹2.17 in 1Q 2023)

Gufic Biosciences Limited to Report Q1, 2024 Results on Aug 11, 2023

Is Gufic Biosciences (NSE:GUFICBIO) Using Too Much Debt?

Investor sentiment improves as stock rises 17%

Gufic Biosciences Limited Recommends Dividend for the Financial Year Ended March 31, 2023

Full year 2023 earnings released: EPS: ₹8.22 (vs ₹9.89 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹2.10 (vs ₹2.17 in 3Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022)

Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022)

Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

These 4 Measures Indicate That Gufic Biosciences (NSE:GUFICBIO) Is Using Debt Reasonably Well

Upcoming dividend of ₹0.10 per share

First quarter 2023 earnings released: EPS: ₹2.17 (vs ₹3.22 in 1Q 2022)

Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Gufic Biosciences Limited, Annual General Meeting, Sep 02, 2022

Gufic Biosciences Limited to Report Q1, 2023 Results on Aug 11, 2022

Investor sentiment improved over the past week

Gufic Biosciences Limited Launches New Drug Delivery System

Full year 2022 earnings released: EPS: ₹9.89 (vs ₹4.56 in FY 2021)

Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Should You Be Adding Gufic Biosciences (NSE:GUFICBIO) To Your Watchlist Today?

Now 21% undervalued

Gufic Biosciences Limited Receives Permission from CDSCO to Manufacture and Sale Isavuconazonium Sulfate API and Finished Formulation Isavuconazole for Injection 200 Mg/Vial

Now 21% undervalued

Gufic Biosciences Limited Receives DCGI Nod for Thymosin Alpha - 1

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock

Second quarter 2022 earnings released: EPS ₹2.41 (vs ₹2.10 in 2Q 2021)

This Is The Reason Why We Think Gufic Biosciences Limited's (NSE:GUFICBIO) CEO Might Be Underpaid

Upcoming dividend of ₹0.10 per share

Is Now The Time To Put Gufic Biosciences (NSE:GUFICBIO) On Your Watchlist?

Investor sentiment improved over the past week

Gufic Biosciences' (NSE:GUFICBIO) Performance Is Even Better Than Its Earnings Suggest

Full year 2021 earnings released: EPS ₹4.56 (vs ₹2.94 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Gufic Biosciences (NSE:GUFICBIO) Before It's Too Late

What Percentage Of Gufic Biosciences Limited (NSE:GUFICBIO) Shares Do Insiders Own?

Gufic Biosciences (NSE:GUFICBIO) Has A Pretty Healthy Balance Sheet

Third quarter 2021 earnings released: EPS ₹1.69 (vs ₹0.90 in 3Q 2020)

Gufic Biosciences Limited to Report Q3, 2021 Results on Feb 08, 2021

Is Gufic Biosciences' (NSE:GUFICBIO) 164% Share Price Increase Well Justified?

Why Gufic Biosciences Limited (NSE:GUFICBIO) Looks Like A Quality Company

Investor sentiment improved over the past week

New 90-day high: ₹131

Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock